REYON Pharmaceutical (102460) Fundamentals 2026 — Revenue Analysis | SniperIQ
REYON Pharmaceutical (102460) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩179.2B, trading at ₩9770.00 on the KSC. This SniperIQ fundamentals page covers REYON Pharmaceutical's valuation, profitability (net margin -28.1%), revenue (₩145.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is REYON Pharmaceutical's market cap?
REYON Pharmaceutical (102460) has a market capitalization of approximately ₩179.2B, trading at ₩9770.00 on the KSC. Market cap moves with the live share price.
What is REYON Pharmaceutical's P/E ratio?
REYON Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is REYON Pharmaceutical?
REYON Pharmaceutical runs a net profit margin of -28.1%, a gross margin of 19.7%, and an operating margin of -23.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does REYON Pharmaceutical generate?
REYON Pharmaceutical reported revenue of ₩145.9B for fiscal year 2025, with net income of -₩29.8B and earnings per share (EPS) of -1604.66. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does REYON Pharmaceutical pay a dividend?
REYON Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is REYON Pharmaceutical financially healthy?
REYON Pharmaceutical carries a debt-to-equity ratio of 1.05x and a current ratio of 0.52x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is REYON Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For REYON Pharmaceutical (102460) the key facts are: market cap ₩179.2B, revenue ₩145.9B, 52-week range 9100-13200. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track REYON Pharmaceutical's full fundamentals live
Get REYON Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.